Latest Pharma and Biotech News
Pharmaceutical
25 November 2024 In what could be construed to be India's quest for pharmaceutical supremacy, a clarion call has been made for the country to set its indigenous standards.
Today's issue
Refine Search
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Pharmaceutical
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) today announced that Dr Thomas Schinecker, chief executive (CEO) of Swiss pharma giant Roche (ROG: SIX), will take up the post as president of the trade association effective January 1, 2025. 26 November 2024
Pharmaceutical
US central nervous system (CNS) disorders specialist Axsome Therapeutics today released encouraging late-stage results for its narcolepsy candidate AXS-12 (reboxetine), sending its shares edging up 2.6% to $100.00 in pre-market activity. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Pharmaceutical
Shares in US biotech major Amgen were 11% lower early on Tuesday. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Biotechnology
South African-Australian private equity firm LeapFrog Investments has announced the close of its fourth fund (Fund IV), with commitments and designated co-investments totalling $1.02 billion. 26 November 2024
Biotechnology
Pyxis Oncology has announced encouraging preliminary data from a Phase I trial of PYX-201, its lead antibody-drug conjugate (ADC), in solid tumors. 26 November 2024
Biotechnology
The Phase III SKYSCRAPER-01 trial has missed its primary endpoint, Swiss cancer giant Roche has reported. 26 November 2024
Pharmaceutical
Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its investigational assets related to the HTI therapeutic HIV vaccine by US antiviral specialist Gilead Sciences. 26 November 2024
Biotechnology
US biopharma Biohaven has provided an update regarding the taldefgrobep alfa development programs in spinal muscular atrophy (SMA) and obesity. 25 November 2024
Biotechnology
Cassava Sciences, a US biotech developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, was trading 83% lower at midday on Thursday. 25 November 2024
Pharmaceutical
Positive top-line results from the Phase III ZENITH study evaluating Winrevair (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) III or IV at high risk of mortality, were released today by US pharma giant Merck & Co. 25 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for belantamab mafodotin in combinations with bortezomib plus dexamethasone (BorDex [BVd]) and pomalidomide plus dexamethasone (PomDex [BPd]) for multiple myeloma patients who have received at least one prior line of therapy. 25 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Imkeldi (imatinib) oral solution, the first oral liquid form of imatinib to treat certain forms of leukemia and other cancers, from privately-held US-Ireland-based pharmaceutical company Shorla Oncology. 25 November 2024
Pharmaceutical
Specialist pre-clinical contract research organization (CRO) and ion channel screening company Metrion Biosciences has announced the appointment of Lee Patterson as its new chief executive. 25 November 2024
Pharmaceutical
Levothyroxine, a widely prescribed treatment for hypothyroidism, may contribute to bone loss in older adults, according to new research presented at the Radiological Society of North America’s (RSNA) annual meeting. 25 November 2024
All news
Biotechnology
Positive top-line results were achieved from COMMAND, a Phase III maintenance study, showing Skyrizi (risankizumab) 180mg or 360mg subcutaneous [SC]) achieved the primary endpoint of clinical remission (per Adapted Mayo Score) at week 52, as well as key secondary endpoints in adult patients with moderately to severely active ulcerative colitis, said the JAK blocker’s developer, AbbVie. 16 June 2023
Biotechnology
The European Medicines Agency (EMA) has validated and accepted for regulatory review the marketing authorization application (MAA) for fruquintinib. 16 June 2023
Pharmaceutical
Rosemont Pharmaceuticals today announced the acquisition of Lucis Pharma, a specialist pharmaceutical business in the UK. 16 June 2023
Biosimilars
Indian drugmakers Alkem Laboratories and Lupin Limited have recently launched the world’s first cetuximab biosimilar in India for the treatment of head and neck cancer (HNC). 16 June 2023
Biosimilars
Medicines for Europe has said that it sees the revision of European Union (EU) pharmaceutical legislation as an opportunity to accelerate patient access to safe, effective, and affordable medicines and to improve security of supply. 15 June 2023
Biotechnology
Advanced cellular and tissue-engineered therapies offer ground-breaking opportunities for the treatment of diseases. Recent years have seen an uptick in the development and regulatory approval of revolutionary biological therapies across the globe.1 15 June 2023
Biotechnology
Eagle-eyed investors might have noticed an omission from a corporate presentation by Axsome Therapeutics, but it does not appear to have damaged optimism generated by the publication. 15 June 2023
Biotechnology
Japanese drug major Astellas Pharma has entered a research collaboration and exclusive option agreement with privately held clinical-stage US biotech firm Cullgen to discover multiple innovative protein degraders. 15 June 2023
Generics
German generics major STADA Arzneimittel has named Christos Gallis as head of Eastern Europe, effective July 1, 2023. 15 June 2023
Biosimilars
Generics and biosimilar medicines company Sandoz has trumpeted the launch of what it calls a ‘global roadmap to increase patient access to biologic medicines’. 15 June 2023
Biotechnology
Seagen has announced an update to the label for its antibody-drug conjugate Adcetris (brentuximab vedotin), adding results from the Phase III ECHELON-1 trial. 15 June 2023
Pharmaceutical
The recent rally in Eli Lilly’s market value, which made it to become the most valuable pharmaceutical company in the world, with a market cap of $420 billion, surpassing Johnson & Johnson, has come as the result of its blockbuster type 2 diabetes (T2D) drug Mounjaro (tirzepatide) successfully completing its second final-stage trial for obesity. 15 June 2023
Biotechnology
US biotech major Gilead Sciences’ Kite unit today announced that its CAR T-cell therapy helped patients with relapsed or refractory large B-cell lymphoma (LBCL) live longer than historic treatment. 15 June 2023
Biotechnology
US biotech giant Amgen has announced that Paul Burton has been appointed as its news chief medical officer (CMO) starting June 26. 15 June 2023
Pharmaceutical
Federal lawmakers in the USA are pushing for a bill that would limit the structure of how pharmacy benefit managers (PMBs) — companies that operate in between insurers, pharmacists and drugmakers — are paid, although a PBM trade group took issue with the proposed legislation, according to Life Sciences Law360. 15 June 2023
Biotechnology
The Commercial Court in Lyon, France, has rejected the request of investment fund Akkadian Partners to postpone the vote on the merger of Erytech with Pherecydes Pharma. 15 June 2023
Pharmaceutical
An investment bank for the UK government has highlighted what it sees as the success of the UK life science sector in raising venture capital in recent years. 15 June 2023
Pharmaceutical
US pharma giant Merck & Co has won out in a lawsuit relating to Bridion (sugammadex), a medication for the reversal of neuromuscular blockade induced by rocuronium and vecuronium in general anesthesia. 14 June 2023
Biotechnology
UK-based ValiRx, a life science company focusing on early-stage cancer therapeutics and women's health, has acquired the scientific assets of Imagen Therapeutics from its appointed liquidators. 14 June 2023
Biotechnology
Privately-held Californian firm Alladapt Immunotherapeutics has announced top-line results from the Phase I/II Harmony study of its multi-targeted allergy treatment ADP101. 14 June 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze